These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8035035)

  • 21. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
    Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccine-induced IgG antibodies to the linear epitope on the PorB outer membrane protein promote opsonophagocytosis of Neisseria meningitidis by human neutrophils.
    Delvig AA; Michaelsen TE; Aase A; Hoiby EA; Rosenqvist E
    Clin Immunol Immunopathol; 1997 Jul; 84(1):27-35. PubMed ID: 9191881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bactericidal activity for Neisseria meningitidis in properdin-deficient sera.
    Söderström C; Braconier JH; Danielsson D; Sjöholm AG
    J Infect Dis; 1987 Jul; 156(1):107-12. PubMed ID: 3110302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).
    Østergaard L; Van der Wielen M; Bianco V; Miller JM
    Int J Infect Dis; 2013 Mar; 17(3):e173-6. PubMed ID: 23246368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals.
    Andreoni J; Käyhty H; Densen P
    J Infect Dis; 1993 Jul; 168(1):227-31. PubMed ID: 8515116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opsonophagocytosis versus complement bactericidal killing as effectors following Neisseria meningitidis group C vaccination.
    Gomez-Lus ML; Giménez MJ; Vázquez JA; Aguilar L; Anta L; Berrón S; Laguna B; Prieto J
    Infection; 2003 Jan; 31(1):51-4. PubMed ID: 12590334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.
    Granoff DM
    Vaccine; 2009 Jun; 27 Suppl 2(Suppl 2):B117-25. PubMed ID: 19477054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bactericidal antibody response to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccine.
    Milagres LG; Gorla MC; Rebelo MC; Barroso DE
    FEMS Immunol Med Microbiol; 2000 Aug; 28(4):319-27. PubMed ID: 10891656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody response to meningococcal polysaccharides A and C in patients with complement defects.
    Biselli R; Casapollo I; D'Amelio R; Salvato S; Matricardi PM; Brai M
    Scand J Immunol; 1993 Jun; 37(6):644-50. PubMed ID: 8316762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.
    Granoff DM; Gupta RK; Belshe RB; Anderson EL
    J Infect Dis; 1998 Sep; 178(3):870-4. PubMed ID: 9728562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone.
    Broderick MP; Romero-Steiner S; Rajam G; Johnson SE; Milton A; Kim E; Choi LJ; Radin JM; Schmidt DS; Carlone GM; Messonnier N; Faix DJ
    Clin Vaccine Immunol; 2016 Aug; 23(8):672-80. PubMed ID: 27280619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Bactericidal antibodies to meningococcal serogroups A, B and C in persons inoculated with a polycomponent meningococcal vaccine].
    Belova TN
    Zh Mikrobiol Epidemiol Immunobiol; 1982 Jan; (1):95-7. PubMed ID: 6805176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased adherence to vaginal epithelial cells and phagocytic killing of gonococci and urogenital meningococci associated with heat modifiable proteins.
    Hagman M; Danielsson D
    APMIS; 1989 Sep; 97(9):839-44. PubMed ID: 2571351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial.
    Lieberman JM; Chiu SS; Wong VK; Partidge S; Chang SJ; Chiu CY; Gheesling LL; Carlone GM; Ward JI
    JAMA; 1996 May; 275(19):1499-503. PubMed ID: 8622225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine.
    Platonov AE; Beloborodov VB; Pavlova LI; Vershinina IV; Käyhty H
    Clin Exp Immunol; 1995 Apr; 100(1):32-9. PubMed ID: 7697919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum bactericidal activity and induction of chemiluminescence of polymorphonuclear leukocytes: complement activation pathway requirements in defense against Neisseria meningitidis.
    Fredlund H; Sjöholm AG; Selander B; Holmström E; Olcén P; Danielsson D
    Int Arch Allergy Immunol; 1993; 100(2):135-43. PubMed ID: 8443467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.
    Tunheim G; Naess LM; Acevedo R; Fjeldheim ÅK; Bolstad K; García L; Cardoso D; Aase A; Zayas C; González H; Rosenqvist E; Norheim G
    Vaccine; 2014 Nov; 32(49):6631-8. PubMed ID: 25305564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meningococcal surrogates of protection--serum bactericidal antibody activity.
    Borrow R; Balmer P; Miller E
    Vaccine; 2005 Mar; 23(17-18):2222-7. PubMed ID: 15755600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.